Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YC-6 Injection for Intracerebral Hemorrhage Phase IIa Trial
CTR20260550Phase 2Active
- Sponsor
- Guangzhou Cellprotek Pharmaceutical Co., Ltd.
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of androtriol in intracerebral hemorrhage (ICH), sponsored by Guangzhou Cellprotek Pharmaceutical Co., Ltd.. Started Mar 2026; status: active.
02
Drugs
androtriol
03
Conditions
intracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on CTR20260550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260550.